Salix Pharmaceuticals (SLXP)

51.43 -0.38  -0.73%  Jun 01, 8:00PM Go Pro
Watch this stock
View Full Chart SLXP Price Chart

Key Stats

Market Cap 3.058B
Revenue Growth 61.60%
Profit Margin 5.82%
Earnings Yield 3.03%
Dividend Yield 0.00%
Earnings Per Share TTM 1.56
PE Ratio 32.98
Price / Sales Ratio 5.048
52 Week High 53.99
52 Week Low 25.64
Beta 0.7826
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

Jun 01 Market Wrap Video + Additions to Watch List http://stks.co/442N including: $AH $LQDT $AMLN $PETM $SLXP by StockTiger
Jun 01 RT @StockTiger Market Wrap Video + Additions to Watch List http://stks.co/43sP including: $AH $LQDT $AMLN $PETM $SLXP by sssc
May 31 Market Wrap Video + Additions to Watch List http://stks.co/43h3 including: $AH $LQDT $AMLN $PETM $SLXP by StockTiger
May 31 SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and ...
May 31 Need a Winner, Just Not at All Costs Fool
May 30 UPDATE 2-Alkermes to halt development of constipation drug
May 29 Over $10 range break watchlist for tmrw: $NTES $PENN $SLXP $CVS $LKQ $EQIX $LII $TWTC $DSW $BBBY $SWI $$LVS $WYNN $SFLY by TheEquitiesRoom
May 29 Salix Pharmaceuticals to Present at Three Investment Conferences in June Business Wire
May 25 Bio-Pharma Stocks To Watch For Next Week
May 25 Friday's Bio Pharma Potential Catalyst Price Movers
May 16 $SLXP nice to see this name holding its 50DMA by TradetheLeaders

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Drugs - Generic

Salix Pharmaceuticals Ltd. develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix also markets OSMOPREP Tablets, VISICOL Tablets, APRISO extended-release capsules, METOZOLV, RELISTOR Subcutaneous Injection, PEPCID for Oral Suspension, Oral Suspension DIURIL, AZASAN Tablets, USP, ANUSOL-HC, ANUSOL-HC Suppository, PROCTOCORT Cream and PROCTOCORT Suppository. Crofelemer, budesonide foam, RELISTOR, Lumacan and rifaximin for additional indications are under development. It was founded by Randy W. Hamilton and Lorin K. Johnson in 1989 and is headquartered in Raleigh, North Carolina.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Salix Pharmaceuticals is up 31.15% over the last year vs S&P 500 Total Return down 0.41%, Progenics Pharmaceuticals up 5.51%, and Cubist Pharmaceuticals up 7.68%.

  • SLXP Total Returns
  • ^SPXTR Total Returns
  • PGNX Total Returns
  • CBST Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Cash Flow Statement View Statement

Get Quote for

Pro Strategies Featuring SLXP

Did Salix Pharmaceuticals make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

SLXP Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
SLXP 51.43 -0.38 -0.73% 3.079B
SLX 40.95 -1.00 -2.38%
SLW 26.64 +1.16 +4.55% 9.008B
VOXX 9.56 -0.30 -3.04% 205.19M
VOX 62.61 -1.55 -2.42%
VOOV 55.76 -1.81 -3.14%
VOG 1.74 -0.13 -6.95% 108.18M
VOD 26.78 -0.01 -0.04% 136.24B
VOCS 15.72 -0.41 -2.54% 327.12M
UTHR 43.01 -1.23 -2.78% 2.373B
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close